1. Subject has failed at least one prior line of therapy and has measurable disease according to RECIST 1.1. Subject may have received chemotherapy or PD-1 or PDL-1 inhibitors. Subjects with known EGFR mutations or ALK or ROS1 gene rearrangements have failed (PD or unacceptable toxicity) at least one prior EGFR or ALK or ROS1 tyrosine kinase inhibitor (TKI), respectively. There is no limit on lines of prior anti-cancer therapy.